Psychosis Associated With Methylphenidate in Children and Adolescents

NCT06518330 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 46233

Last updated 2024-07-24

No results posted yet for this study

Summary

perform a study in VigiBase® to assess if methylphenidate was associated with an over-reporting of psychosis including hallucinations in children and adolescents and to characterize those psychosis.

Conditions

Interventions

DRUG

Intake of Methylphenidate

Intake of Methylphenidate

Sponsors & Collaborators

  • University Hospital, Caen

    lead OTHER

Eligibility

Min Age
5 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1967-01-01
Primary Completion
2024-02-16
Completion
2024-02-16
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06518330 on ClinicalTrials.gov